Amgen Inc. (NASDAQ:AMGN) Stock Has Consensus Price Target of $387.93 According to Analysts

Posted by Geri Gentry on Oct 23rd, 2026

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have received a consensus rating of “Hold” from the thirty ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $388.64.

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group upped their price target on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Mizuho lifted their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. HSBC cut shares of Amgen from a “buy” rating to a “hold” rating and dropped their target price for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. Barclays raised their price target on Amgen from $380.00 to $400.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Sanford C. Bernstein boosted their target price on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th.

Check Out Our Latest Report on AMGN

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. Insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. State Street Corp grew its stake in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amgen by 12.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after acquiring an additional 605,928 shares during the period. Bank of America Corp DE purchased a new position in shares of Amgen in the second quarter valued at $1,831,903,000. Finally, Amundi lifted its holdings in Amgen by 15.2% during the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock worth $1,408,715,000 after purchasing an additional 512,883 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 2.0%

AMGN opened at $447.28 on Friday. Amgen has a twelve month low of $288.00 and a twelve month high of $450.98. The business has a 50 day moving average price of $417.22 and a 200 day moving average price of $377.39. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm has a market cap of $241.81 billion, a P/E ratio of 27.80, a price-to-earnings-growth ratio of 3.21 and a beta of 0.41.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter last year, the company earned $6.02 earnings per share. The firm’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen will post 22.94 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Piper Sandler maintained a Buy rating and set a $457 price target, leaving additional upside from the stock’s latest 52-week high. Piper Sandler Remains a Buy on Amgen
Positive Sentiment: Amgen reached a new 52-week high at $447.28, roughly 55% above its October lows, highlighting strong investor momentum and demand for the stock. Amgen Reaches a New 52-Week High
Positive Sentiment: Amgen and AstraZeneca reported Phase III Tezspire data in eosinophilic esophagitis, a potential expansion opportunity for the drug and a catalyst for the companies’ respiratory-immunology portfolios. Amgen and AstraZeneca Report Phase III Tezspire Data
Positive Sentiment: Recent fundamentals remain supportive: Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Its diversified oncology, rare-disease, and inflammation portfolio also provides a steadier cash-flow profile than some high-growth biotech peers.

About Amgen

(Get Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.